New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
10:15 EDTHAENASDAQ to cancel Haemonetics trades at or below $36.28 from 9:29-9:30 am ET
NASDAQ said it investigated potentially erroneous transactions involving Haemonetics' (HAE) stock and determined to cancel all trades in the security at or below $36.28 that were executed in NASDAQ between 09:29:00 and 09:30:00 ET. Reference Link
News For HAE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 5, 2015
18:56 EDTHAEOn The Fly: After Hours Movers
HIGHER: Regulus Therapeutics (RGLS), up 8.7% after the company announced that it will present new preclinical data on RG-012 for kidney disease... Palatin Technologies (PTN), up 9.6% after director Robert deVeer Jr. buys 10,000 shares of common stock... Arena Pharmaceuticals (ARNA), up 4.7% after CEO Jack Lief announced his retirement and Harry Hixson was named interim CEO... DuPont (DD), up 5.9% after CEO and chair Ellen Kullman retires... Ruckus Wireless (RKUS), up 4.9% after joining the S&P 600... Starz (STRZA), up 10.1% after the LA Times reports that Lionsgate (LGF) is in advanced talks to merge with Starz. DOWN AFTER EARNINGS: Container Store (TCS), down 10.4%. ALSO LOWER: Sarepta Therapeutics (SRPT), down 3.8% after filing to sell $125M of common stock... Haemonetics (HAE), down 12.2% after lowering its fiscal 2016 outlook... Energy XXI (EXXI), down 8.3% after filing a $500M mixed securities shelf... Mallinckrodt (MNK), down 1.6% after announcing that it will provide a business update and financial guidance for the fiscal year ending September 30, 2016, on an investor call on October 6.
16:48 EDTHAEHaemonetics sees FY16 constant currency revenue growth approximately 4%
Down from prior view of 7%-9% constant currency revenue growth for FY16. Revenue consensus for FY16 is $946.75M.
16:40 EDTHAEHaemonetics says shortfall in 2H16 revenue due to deterioration in Russia
Subscribe for More Information
16:38 EDTHAEHaemonetics lowers FY16 adjusted EPS view to $1.65-$1.75 from $1.98-$2.08
Subscribe for More Information
16:36 EDTHAEHaemonetics sees Q2 adjusted EPS approximately 40c, consensus 39c
Subscribe for More Information
16:36 EDTHAEHaemonetics lowers FY16 outlook
Subscribe for More Information
September 29, 2015
16:38 EDTHAEHaemonetics CEO Brian Concannon resigns, Ron Gelman appointed interim CFO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use